BPG is committed to discovery and dissemination of knowledge
Featured Articles
7/21/2021 9:37:44 AM | Browse: 593 | Download: 1610
 |
Received |
|
2021-02-03 15:15 |
|
Peer-Review Started |
|
2021-02-03 15:16 |
|
First Decision by Editorial Office Director |
|
2021-03-31 04:59 |
|
Return for Revision |
|
2021-03-31 04:59 |
|
Revised |
|
2021-04-04 12:47 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2021-06-03 08:02 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2021-06-03 12:02 |
|
Articles in Press |
|
2021-06-03 12:02 |
|
Edit the Manuscript by Language Editor |
|
2021-06-13 21:00 |
|
Typeset the Manuscript |
|
2021-07-20 04:42 |
|
Publish the Manuscript Online |
|
2021-07-21 09:30 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Mechanisms of acquired resistance of BRCA1/2-driven tumors to platinum compounds and PARP inhibitors
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Evgeny Imyanitov and Anna Sokolenko |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Ministry of Science and Higher Education of the Russian Federation |
15-2020-789 |
|
| Corresponding Author |
Evgeny Imyanitov, MD, Professor, Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Pesochny, Leningradskaya str. 68, Saint-Petersburg 197758, Russia. evgeny@imyanitov.spb.ru |
| Key Words |
BRCA1/2 mutations; platinum-based therapy; Poly (ADP-ribose) polymerase inhibitors; drug resistance; Secondary mutations; Intratumoral heterogeneity; Neoadjuvant therapy |
| Core Tip |
BRCA1/2-associated tumors are highly sensitive to platinum compounds and poly (ADP-ribose) polymerase inhibitors, however they eventually acquire resistance to this type of therapy. Restoration of BRCA1/2 function via the second mutation is the most known mechanism of tumor adaptation to the therapeutic pressure. Some studies demonstrate that even chemonaive BRCA1-driven tumors contain a small fraction of BRCA1-proficient cells, suggesting that the loss of the remaining allele of this gene is not the first event in tumor pathogenesis. These pre-existing platinum-resistant cells rapidly repopulate tumor mass during neoadjuvant therapy for ovarian cancer and explain inevitability of the disease relapses after seemingly successful surgical debulking. |
| Publish Date |
2021-07-21 09:30 |
| Citation |
Imyanitov E, Sokolenko A. Mechanisms of acquired resistance of BRCA1/2-driven tumors to platinum compounds and PARP inhibitors. World J Clin Oncol 2021; 12(7): 544-556 |
| URL |
https://www.wjgnet.com/2218-4333/full/v12/i7/544.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v12.i7.544 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
